Tags: Rucaparib
PARP Inhibitors in Prostate Cancer: Practical Guidance for Busy Clinicians
Abstract: The management of prostate cancer entered a new era of biomarker-driven therapy in May of 2020, when the US Food and Drug Administration (FDA) […]
Hem/Onc News
Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]